FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Phase 2
Recruiting
- Conditions
- Prostate Cancer (Adenocarcinoma)Prostate CAProstate CancersProstate Cancer (Post Prostatectomy)Prostate CancerProstate Cancer Patients Undergoing Radical ProstatectomyHigh-risk Prostate Cancer
- Interventions
- Biological: Standard of Care (SOC)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Cellvax Therapeutics Inc
- Target Recruit Count
- 100
- Registration Number
- NCT06636682
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic, Chicago, Illinois, United States
🇺🇸Central Ohio Urology Group, Gahanna, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath